Study of Non Inferiority Bi-Profenid® 200mg Versus Bi-Profenid® 300mg Among Patients Presenting of the Post-traumatic or Rheumatologic Acute Affections of the Locomotor Apparatus (BIPROPAIN)

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary objective:

To demonstrate the non-inferiority of Bi-Profenid 100 mg x 2 day versus Bi-Profenid 150 mg x 2 day in patients presenting with pain related to closed, benign, acute post-traumatic conditions of the motor system or acute, non-infectious rheumatologic conditions, by comparing, on the one hand, changes in resting pain intensity over the entire day, measured at the end of the day using a numeric scale (NS), over 5 days and, on the other hand, total intake over 5 days of concomitant analgesics.

Secondary Objectives:

• To describe concomitant analgesic treatments

• To describe the time between baseline and use of a step I, II or III analgesic

• To evaluate patients pain relief using a Likert 4-class scale (complete or substantial relief, moderate relief slight relief and absence of relief) at D5

• To evaluate changes in intensity of pain when moving, over the entire day, measured at the end of the day using a numeric scale, over 5 days

• To evaluate the patients overall satisfaction at the end of treatment using a 4-point Simple Verbal Scale (SVS) (very satisfied, somewhat satisfied, somewhat unsatisfied, very unsatisfied)

• To evaluate the patients overall satisfaction at the end of the study using a 4-point Simple Verbal Scale (EVS) (very satisfied, somewhat satisfied, somewhat unsatisfied, very unsatisfied)

• To compare the safety of the two treatments

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Treatments: Ketoprofen

Criteria

Inclusion criteria :

• Male or female, more than 18 and less than 65 years of age,

• Women using a method of contraception and with a negative pregnancy test before entering the study, or women who have been menopausal for at least 1 year,

• Patients meeting one of the following criteria:

• Closed benign trauma of the motor system occurring within the last 24 hours,

• Contusion of the motor system occurring within the last 24 hours,

• Acute rheumatologic conditions (acute lower back pain, lumbar sciatica, cervicobrachial neuralgia),

• Abarticular rheumatism,

• Requiring treatment with Bi-Profenid for 5 days,

• With resting pain intensity measured on a numeric scale at baseline >or= 3 (before administration of any treatment),

• Receiving a prior medical examination suited to the study

Exclusion criteria :

• Need for surgery,

• Need for hospitalization,

• Need for an analgesic other than step I at the baseline visit,

• Need for treatment with another selective or non-selective NSAID (per os and/or topical), including aspirin, selective cyclo-oxygenase 2 inhibitors, corticosteroids or muscle relaxants at baseline and throughout the study,

• Serious trauma: knee luxation, any fracture, ruptures such as Achilles tendon rupture,

• Sprain treated with a cast,

• Bursitis,

• Local and/or general severe infection,

• Pregnant or nursing women,

• Hypersensitivity to ketoprofen or to any of the excipients of the product,

• Previous history of asthma triggered by taking ketoprofen or substances with similar activity such as other NSAIDs or aspirin,

• Gastrointestinal haemorrhage, cerebrovascular haemorrhage or other active haemorrhage,

• Previous history of digestive haemorrhage or perforation during previous NSAID treatment,

• Active intestinal ulcer,

• Active peptic ulcer, previous history of peptic ulcer or recurrent haemorrhage (2 separate episodes or more of haemorrhage or ulcerations detected),

• Severe hepatic failure,

• Severe renal failure,

• Severe heart failure,

• Uncontrolled hypertension,

• Hypersensitivity or intolerance to gluten, due to the presence of wheat starch (gluten),

• Patients treated with oral anticoagulants, heparins, platelet antiaggregants, selective serotonin reuptake inhibitors (SSRI), lithium, methotrexate, pemetrexed and immunosuppressants

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.